Gefitinib Analogue V1801 Induces Apoptosis of T790M EGFR-Harboring Lung Cancer Cells by Up-Regulation of the BH-3 Only Protein Noxa

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Zhang, Bo ^a,c   Jiao, Jiao ^b   Liu, Ying ^d   Guo, Liang Xia ^a   Zhou, Bo ^a   Li, Gang Qin ^b   Yao, Zhu Jun ^b   Zhou, Guang Biao ^a  

^a INSTITUTE OF ZOOLOGY   (China)

^b SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; N (2 BROMO 5 (TRIFLUOROMETHYL)PHENYL) 6 METHOXY 7 (3 (PIPERIDIN 1 YL)PROPOXY)QUINAZOLIN 4 AMINE; PROTEIN NOXA; TETRAZOLIUM; UNCLASSIFIED DRUG; V 1801;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CHROMATIN CONDENSATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VIVO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84869765785     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048748     Document Type: Article

References (46)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Herbst RS, Heymach JV, Lippman SM, (2008) Lung Cancer. N Engl J Med 359: 1367-1380.
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. N Engl J Med 350: 2129-2139.
4. Ciardiello F, Tortora G, (2008) EGFR Antagonists in Cancer Treatment. N Engl J Med 358: 1160-1174.
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. N Engl J Med 353: 123-132.
6. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain. PLoS Med 2: e73 doi:10.1371/journal.pmed.0020073.
7. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
8. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, et al. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105: 2070-2075.
9. Kim Y, Ko J, Cui Z, Abolhoda A, Ou S-HI, et al. (2012) The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Ther 10.1158/1535-7163.MCT-11-0750.
10. Hanahan D, Weinberg RA, (2011) Hallmarks of Cancer: The Next Generation. Cell 144: 646-674.
11. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR, (2010) The BCL-2 family reunion. Mol Cell 37: 299-310.
12. Youle RJ, Strasser A, (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59 10.1038/nrm2308.
13. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, et al. (2006) The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 107: 257-264.
14. Kim JY, Ahn HJ, Ryu JH, Suk K, Park JH, (2004) BH3-only protein Noxa Is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1α. J Exp Med 199: 113-124.
15. Sheridan C, Brumatti G, Elgendy M, Brunet M, Martin SJ, (2010) An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs. Oncogene 29: 6428-6441.
16. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, et al. (2000) Noxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis. Science 288: 1053-1058.
17. Schuler M, Maurer U, Goldstein JC, Breitenbucher F, Hoffarth S, et al. (2003) p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation. Cell Death Differ 10: 451-460.
18. Willis SN, Chen L, Dewson G, Wei A, Naik E, et al. (2005) Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19: 1294-1305.
19. Lowman XH, McDonnell MA, Kosloske A, Odumade OA, Jenness C, et al. (2010) The Proapoptotic Function of Noxa in Human Leukemia Cells Is Regulated by the Kinase Cdk5 and by Glucose. Mol Cell 40: 823-833.
20. Elgendy M, Sheridan C, Brumatti G, Martin SJ, (2011) Oncogenic Ras-Induced Expression of Noxa and Beclin-1 Promotes Autophagic Cell Death and Limits Clonogenic Survival. Mol cell 42: 23-35.
21. Hershko T, Ginsberg D, (2004) Up-regulation of Bcl-2 Homology 3 (BH3)-only Proteins by E2F1 Mediates Apoptosis. J Biol Chem 279: 8627-8634.
22. Nikiforov MA, Riblett M, Tang WH, Gratchouck V, Zhuang D, et al. (2007) Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci U S A 104: 19488-19493.
23. Wang Q, Mora-Jensen H, Weniger MA, Perez-Galan P, Wolford C, et al. (2009) ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci U S A 106: 2200-2205.
24. Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, et al. (1996) NCI-navy medical oncology branch cell line data base. J Cell Biochem 63 S24: 32-91 10.1002/jcb.240630505.
25. Sordella R, Bell DW, Haber DA, Settleman J, (2004) Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways. Science 305: 1163-1167.
26. Tang Z, Du R, Jiang S, Wu C, Barkauskas DS, et al. (2008) Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 99: 911-922.
27. Fang HT, Zhang B, Pan XF, Gao L, Zhen T, et al. (2012) Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells. Proc Natl Acad Sci U S A 109: 2521-2526.
28. Ma L, Wen ZS, Liu Z, Hu Z, Ma J, et al. (2011) Overexpression and Small Molecule-Triggered Downregulation of CIP2A in Lung Cancer. PLoS ONE 6: e20159.
29. Hu Z, Pan XF, Wu FQ, Ma LY, Liu DP, et al. (2009) Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia. PLoS ONE 4: e6257.
30. Chou TC, Talalay P, (1981) Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 115: 207-216.
31. Han J, Goldstein LA, Hou W, Rabinowich H, (2007) Functional Linkage between NOXA and Bim in Mitochondrial Apoptotic Events. J Biol Chem 282: 16223-16231.
32. Ploner C, Kofler R, Villunger A, (2008) Noxa: at the tip of the balance between life and death. Oncogene 27: S84-S92.
33. Yin X, Giap C, Lazo JS, Prochownik EV, (2003) Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 22: 6151-6159.
34. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, et al. (2005) Erlotinib in Lung Cancer - Molecular and Clinical Predictors of Outcome. N Engl J Med 353: 133-144.
35. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
36. Zhou W, Ercan D, Chen L, Yun CH, Li D, et al. (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462: 1070-1074 10.1038/nature08622.
37. Wu X, Li M, Tang W, Zheng Y, Lian J, et al. (2011) Design, Synthesis, and In vitro Antitumor Activity Evaluation of Novel 4-pyrrylamino Quinazoline Derivatives. Chem Biol Drug Design 78: 932-940 10.1111/j.1747-0285.2011.01234.x.
38. Lessene G, Czabotar PE, Colman PM, (2008) BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 7: 989-1000 10.1038/nrd2658.
39. Llambi F, Green DR, (2011) Apoptosis and oncogenesis: give and take in the BCL-2 family. Curr Opin Genet Dev 21: 12-20 doi: 10.1016/j.gde.2010.12.001.
40. Hauck P, Chao BH, Litz J, Krystal GW, (2009) Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol Cancer Ther 8: 883-892.
41. Lin CL, Tseng HC, Chen WP, Su MJ, Fang KM, et al. (2011) Intracellular zinc release-activated ERK-dependent GSK-3[beta]-p53 and Noxa-Mcl-1 signaling are both involved in cardiac ischemic-reperfusion injury. Cell Death Differ 18: 1651-1663.
42. Dang CV, (1999) c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism. Mol Cellular Biol 19: 1-11.
43. Hoffman B, Liebermann DA, (2008) Apoptotic signaling by c-MYC. Oncogene 27: 6462-6472.
44. Tong JS, Zhang QH, Huang X, Fu XQ, Qi ST, et al. (2011) Icaritin Causes Sustained ERK1/2 Activation and Induces Apoptosis in Human Endometrial Cancer Cells. PLoS ONE 6: e16781 doi:10.1371/journal.pone.0016781.
45. Mei Y, Xie C, Xie W, Tian X, Li M, et al. (2007) Noxa/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis. Neoplasia 9: 871-881.
46. Liu Y, Chen XQ, Liang HX, Zhang FX, Zhang B, et al. (2011) Small Compound 6-O-Angeloylplenolin Induces Mitotic Arrest and Exhibits Therapeutic Potentials in Multiple Myeloma. PLoS ONE 6: e21930.